Zoar (ZOAR) completed its business combination with Impact Biomedical, which survived the merger as a wholly owned subsidiary of Zoar.
Each Impact common share was converted into the right to receive one Zoar ordinary share. Zoar also acquired all outstanding Zoar Labs shares from Dr. Kanans Visvanats in exchange for Zoar ordinary shares. Zoar expects NYSE American trading to begin November 18, 2026. After closing, Zoar had approximately 180.0 million ordinary shares outstanding; Visvanats held approximately 93.32% and former Impact stockholders held approximately 4.80%.
For the fiscal year ended March 31, 2026, Zoar Labs reported revenue up approximately 17.1% to $651.7 million from $556.4 million and net income up approximately 23.9% to $77.7 million from $62.7 million, both compared with the prior fiscal year.